QuickView: Positive data announced for CRLX101 in RCC
In conjunction with its FY14 results, Cerulean announced strong top-line interim data for CRLX101 in its lead indication of relapsed renal cell carcinoma (RCC). The combination treatment with Avastin achieved its primary endpoint of four-month progression free survival (PFS) in at least 50% of patients, showing significant improvement over the current standard of care. Cerulean also confirmed that current cash holdings and recent financing with Hercules provide the company with resources to fund ongoing trials for both CRLX101 and CRLX301 through to Q316.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.